Selecta Biosciences raises $15.1 million in series B financing

Existing investors, Polaris Venture Partners and Flagship Ventures were joined by NanoDimension and professor Timothy Springer.

The proceeds of this financing will be used to expand Selecta’s R&D efforts and to advance the lead product candidate through initial clinical evaluation.

Robert Bratzler, executive chairman of Selecta, said: “I am pleased by the strength of our investors whose track record of creating successful companies is a loud validation of our team, technology platform, and product opportunities. I’m equally pleased by the enormous shareholder value that was created since our initial financing.”